APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pneumococcal Vaccine

Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.

There are two types of Pneumococcal Vaccine: conjugate vaccines and polysaccharide vaccines.

23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).

Selected research

Market Outlook & Growth Opportunities

Global Pneumococcal Vaccine Market Outlook and Growth Opportunities 2026

25 December 2025193 pages

Choose your research edition.

Industry ResearchPneumococcal Vaccine Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumococcal Vaccine Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Pneumococcal Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumococcal Vaccine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumococcal Vaccine Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.

There are two types of Pneumococcal Vaccine: conjugate vaccines and polysaccharide vaccines.

23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).

Read the full market overview

At present, only MSD, Sanofipasteur and CDIBP can produce PPSV 23, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. As for PCV 13, only Pfizer can supply it. And GSK is the only one manufacturing PCV 10. However, there are some companies working on research of Pneumococcal Vaccine. Pfizer is the leader of this industry with 84% market shares.

North America is the largest consumption market of Pneumococcal Vaccine with sales market share nearly 40%. The second place is Europe, following North America with sales market share over 18%. Asia-Pacific is another important market of Pneumococcal Vaccine, enjoy nearly 16% sales market share, but the consumption experienced a sharp decrease due to approval of government departments in last few years.

This report provides an overview of the global Pneumococcal Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pneumococcal Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pneumococcal Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pneumococcal Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Pneumococcal Vaccine Segment by Company

Pfizer

GSK

MSD

Sanofipasteur

CDIBP

Pneumococcal Vaccine Segment by Type

PPSV 23

PCV 7/13

PCV 10

Pneumococcal Vaccine Segment by End User

Child

Adult

Pneumococcal Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pneumococcal Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pneumococcal Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pneumococcal Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Pneumococcal Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pneumococcal Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pneumococcal Vaccine industry.

Chapter 3: Detailed analysis of Pneumococcal Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pneumococcal Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pneumococcal Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pneumococcal Vaccine Industry Trends Table 2. Pneumococcal Vaccine Industry Drivers Table 3. Pneumococcal Vaccine Industry Opportunities and Challenges Table 4. Pneumococcal Vaccine Industry Restraints Table 5. Global Pneumococcal Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pneumococcal Vaccine Revenue Share by Company (2021-2026) Table 7. Global Pneumococcal Vaccine Sales Volume by Company (K Doses) & (2021-2026) Table 8. Global Pneumococcal Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Pneumococcal Vaccine Average Price (USD/Dose) of Company (2021-2026) Table 10. Global Pneumococcal Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pneumococcal Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Pneumococcal Vaccine Company, Product Type & Application Table 13. Global Pneumococcal Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pneumococcal Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of PPSV 23 Table 18. Significant Companies of PCV 7/13 Table 19. Significant Companies of PCV 10 Table 20. Global Pneumococcal Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Doses) Table 21. Global Pneumococcal Vaccine Sales Volume by Type (2021-2026) & (K Doses) Table 22. Global Pneumococcal Vaccine Sales Volume by Type (2027-2032) & (K Doses) Table 23. Global Pneumococcal Vaccine Sales Volume Share by Type (2021-2026) Table 24. Global Pneumococcal Vaccine Sales Volume Share by Type (2027-2032) Table 25. Global Pneumococcal Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Pneumococcal Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Pneumococcal Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Pneumococcal Vaccine Sales Value Share by Type (2021-2026) Table 29. Global Pneumococcal Vaccine Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Child Table 31. Significant Companies of Adult Table 32. Global Pneumococcal Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Doses) Table 33. Global Pneumococcal Vaccine Sales Volume by Application (2021-2026) & (K Doses) Table 34. Global Pneumococcal Vaccine Sales Volume by Application (2027-2032) & (K Doses) Table 35. Global Pneumococcal Vaccine Sales Volume Share by Application (2021-2026) Table 36. Global Pneumococcal Vaccine Sales Volume Share by Application (2027-2032) Table 37. Global Pneumococcal Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Pneumococcal Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Pneumococcal Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Pneumococcal Vaccine Sales Value Share by Application (2021-2026) Table 41. Global Pneumococcal Vaccine Sales Value Share by Application (2027-2032) Table 42. Global Pneumococcal Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Table 43. Global Pneumococcal Vaccine Sales by Region (2021-2026) & (K Doses) Table 44. Global Pneumococcal Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Pneumococcal Vaccine Sales by Region (2027-2032) & (K Doses) Table 46. Global Pneumococcal Vaccine Sales Market Share by Region (2027-2032) Table 47. Global Pneumococcal Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Pneumococcal Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Pneumococcal Vaccine Sales Value Share by Region (2021-2026) Table 50. Global Pneumococcal Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Pneumococcal Vaccine Sales Value Share by Region (2027-2032) Table 52. Global Pneumococcal Vaccine Market Average Price (USD/Dose) by Region (2021-2026) Table 53. Global Pneumococcal Vaccine Market Average Price (USD/Dose) by Region (2027-2032) Table 54. Global Pneumococcal Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Doses) Table 55. Global Pneumococcal Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Pneumococcal Vaccine Sales by Country (2021-2026) & (K Doses) Table 57. Global Pneumococcal Vaccine Sales Market Share by Country (2021-2026) Table 58. Global Pneumococcal Vaccine Sales by Country (2027-2032) & (K Doses) Table 59. Global Pneumococcal Vaccine Sales Market Share by Country (2027-2032) Table 60. Global Pneumococcal Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Pneumococcal Vaccine Sales Value Market Share by Country (2021-2026) Table 62. Global Pneumococcal Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Pneumococcal Vaccine Sales Value Market Share by Country (2027-2032) Table 64. Pfizer Company Information Table 65. Pfizer Business Overview Table 66. Pfizer Pneumococcal Vaccine Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 67. Pfizer Pneumococcal Vaccine Product Portfolio Table 68. Pfizer Recent Development Table 69. GSK Company Information Table 70. GSK Business Overview Table 71. GSK Pneumococcal Vaccine Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 72. GSK Pneumococcal Vaccine Product Portfolio Table 73. GSK Recent Development Table 74. MSD Company Information Table 75. MSD Business Overview Table 76. MSD Pneumococcal Vaccine Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 77. MSD Pneumococcal Vaccine Product Portfolio Table 78. MSD Recent Development Table 79. Sanofipasteur Company Information Table 80. Sanofipasteur Business Overview Table 81. Sanofipasteur Pneumococcal Vaccine Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 82. Sanofipasteur Pneumococcal Vaccine Product Portfolio Table 83. Sanofipasteur Recent Development Table 84. CDIBP Company Information Table 85. CDIBP Business Overview Table 86. CDIBP Pneumococcal Vaccine Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 87. CDIBP Pneumococcal Vaccine Product Portfolio Table 88. CDIBP Recent Development Table 89. Key Raw Materials Table 90. Raw Materials Key Suppliers Table 91. Pneumococcal Vaccine Distributors List Table 92. Pneumococcal Vaccine Customers List Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. Pneumococcal Vaccine Product Image Figure 2. Global Pneumococcal Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pneumococcal Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pneumococcal Vaccine Sales (2021-2032) & (K Doses) Figure 5. Global Pneumococcal Vaccine Sales Average Price (USD/Dose) & (2021-2032) Figure 6. Global Pneumococcal Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. PPSV 23 Image Figure 10. PCV 7/13 Image Figure 11. PCV 10 Image Figure 12. Global Pneumococcal Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Doses) Figure 13. Global Pneumococcal Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Pneumococcal Vaccine Sales Volume Share by Type (2021-2032) Figure 15. Global Pneumococcal Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Pneumococcal Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Pneumococcal Vaccine Sales Value Share by Type (2021-2032) Figure 18. Child Image Figure 19. Adult Image Figure 20. Global Pneumococcal Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Doses) Figure 21. Global Pneumococcal Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Pneumococcal Vaccine Sales Volume Share by Application (2021-2032) Figure 23. Global Pneumococcal Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Pneumococcal Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Pneumococcal Vaccine Sales Value Share by Application (2021-2032) Figure 26. Global Pneumococcal Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Figure 27. Global Pneumococcal Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Pneumococcal Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Pneumococcal Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Pneumococcal Vaccine Sales Value (2021-2032) & (US$ Million) Figure 31. North America Pneumococcal Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Pneumococcal Vaccine Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Pneumococcal Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Pneumococcal Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Pneumococcal Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Pneumococcal Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. South America Pneumococcal Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Pneumococcal Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Pneumococcal Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Pneumococcal Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Pneumococcal Vaccine Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Pneumococcal Vaccine Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • PPSV 23
  • PCV 7/13
  • PCV 10
Applications
  • Child
  • Adult
Companies covered
  • Pfizer
  • GSK
  • MSD
  • Sanofipasteur
  • CDIBP

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pneumococcal Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Pneumococcal Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Pneumococcal Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pneumococcal Vaccine Market Dynamics
  1. 2.1 Pneumococcal Vaccine Industry Trends
  2. 2.2 Pneumococcal Vaccine Industry Drivers
  3. 2.3 Pneumococcal Vaccine Industry Opportunities and Challenges
  4. 2.4 Pneumococcal Vaccine Industry Restraints
3 Pneumococcal Vaccine Market by Company
  1. 3.1 Global Pneumococcal Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Pneumococcal Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Pneumococcal Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Pneumococcal Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Pneumococcal Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Pneumococcal Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Pneumococcal Vaccine Company Product Type and Application
  8. 3.8 Global Pneumococcal Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pneumococcal Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pneumococcal Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pneumococcal Vaccine Market by Type
  1. 4.1 Pneumococcal Vaccine Type Introduction
  2. 4.1.1 PPSV 23
  3. 4.1.2 PCV 7/13
  4. 4.1.3 PCV 10
  5. 4.2 Global Pneumococcal Vaccine Sales Volume by Type
  6. 4.2.1 Global Pneumococcal Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pneumococcal Vaccine Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Pneumococcal Vaccine Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Pneumococcal Vaccine Sales Value by Type
  10. 4.3.1 Global Pneumococcal Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Pneumococcal Vaccine Sales Value by Type (2021-2032)
  12. 4.3.3 Global Pneumococcal Vaccine Sales Value Share by Type (2021-2032)
5 Pneumococcal Vaccine Market by Application
  1. 5.1 Pneumococcal Vaccine Application Introduction
  2. 5.1.1 Child
  3. 5.1.2 Adult
  4. 5.2 Global Pneumococcal Vaccine Sales Volume by Application
  5. 5.2.1 Global Pneumococcal Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Pneumococcal Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Pneumococcal Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Pneumococcal Vaccine Sales Value by Application
  9. 5.3.1 Global Pneumococcal Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Pneumococcal Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Pneumococcal Vaccine Sales Value Share by Application (2021-2032)
6 Pneumococcal Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Pneumococcal Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pneumococcal Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Pneumococcal Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Pneumococcal Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Pneumococcal Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pneumococcal Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pneumococcal Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pneumococcal Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Pneumococcal Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pneumococcal Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Pneumococcal Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pneumococcal Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Pneumococcal Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pneumococcal Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pneumococcal Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pneumococcal Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Pneumococcal Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pneumococcal Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pneumococcal Vaccine Sales Value Share by Country, 2025 VS 2032
7 Pneumococcal Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Pneumococcal Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pneumococcal Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pneumococcal Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Pneumococcal Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Pneumococcal Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Pneumococcal Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pneumococcal Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pneumococcal Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pneumococcal Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pneumococcal Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pneumococcal Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Pneumococcal Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Pneumococcal Vaccine Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 GSK
  8. 8.2.1 GSK Company Information
  9. 8.2.2 GSK Business Overview
  10. 8.2.3 GSK Pneumococcal Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GSK Pneumococcal Vaccine Product Portfolio
  12. 8.2.5 GSK Recent Developments
  13. 8.3 MSD
  14. 8.3.1 MSD Company Information
  15. 8.3.2 MSD Business Overview
  16. 8.3.3 MSD Pneumococcal Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 MSD Pneumococcal Vaccine Product Portfolio
  18. 8.3.5 MSD Recent Developments
  19. 8.4 Sanofipasteur
  20. 8.4.1 Sanofipasteur Company Information
  21. 8.4.2 Sanofipasteur Business Overview
  22. 8.4.3 Sanofipasteur Pneumococcal Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sanofipasteur Pneumococcal Vaccine Product Portfolio
  24. 8.4.5 Sanofipasteur Recent Developments
  25. 8.5 CDIBP
  26. 8.5.1 CDIBP Company Information
  27. 8.5.2 CDIBP Business Overview
  28. 8.5.3 CDIBP Pneumococcal Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 CDIBP Pneumococcal Vaccine Product Portfolio
  30. 8.5.5 CDIBP Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pneumococcal Vaccine Value Chain Analysis
  2. 9.1.1 Pneumococcal Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pneumococcal Vaccine Sales Mode & Process
  6. 9.2 Pneumococcal Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pneumococcal Vaccine Distributors
  9. 9.2.3 Pneumococcal Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst